Neurocrine Biosciences - the Blockbuster INGREZZA and a Promising Pipeline Lead to Rising Results!
Reading Time: 1 minute
Business drivers: Neurocrine Biosciences (NBIX) specializes in developing medications for the treatment of neurodegenerative diseases. One of its key products is Ingrezza (valbenazine). It is used for the treatment of tardive dyskinesia (TD). With prescription capsules, adults can better suppress Parkinson-like symptoms such as uncontrolled facial movements, mobility and gait disorders, tremors, etc. For 2025, Neurocrine Biosciences is targeting peak sales of $2.5-2.6 billion. On April 14, Needham raised the rating to Buy and the price target...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
